Term
| may have accumulation and increased SEs of some antidepressants; do not metabolize codeine and its active metabolite so have reduced analgesia |
|
Definition
|
|
Term
| may have increased risk of CV death, MI, or stroke compared to others better able to convert the prodrug to the active metabolite |
|
Definition
| CYP2C19 poor metabolizers |
|
|
Term
| Gilbert's syndrome; Ironotecan having higher incidence of diarrhea and neutropenia |
|
Definition
| UGT1A1 alterations (UGT1A1*28) |
|
|
Term
| transports drugs into the GI tract; out of the brain; into the renal tubules |
|
Definition
|
|
Term
| P-glycoprotein (efflux transporters) |
|
Definition
| Colchicine, Immunosuppressive agents, Glycosides, Steroids, Antiretroviral agents |
|
|
Term
| Directional movement of drugs across organs; substrates of this secretory pathway are strikingly diverse |
|
Definition
| OATs (uptake transporters) |
|
|
Term
| Lactam antibiotics, Probenecid, Loops and thiazide diuretics, ACE inhibitors, statins |
|
Definition
| substrates of the OAT pathway |
|
|
Term
| can cause warfarin resistance that necessitates daily doses in excess of 15 mg/day |
|
Definition
| coding-region mutations in the CKORC1 gene |
|
|
Term
| can result in sensitivity to warfarin such that doses less than 1 mg/day are sufficient to achieve anticoagulation |
|
Definition
| mutations in the CYP2C9 (especially homozygosity for CYP2C9*3 allele |
|
|
Term
| also influences warfarin dose across the "normal" dosing range |
|
Definition
| non-coding region polymorphisms in VKORC1 |
|
|
